Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Clinical Oncology Fellow, Medicine, Johns Hopkins University 1992 - 1996
  • Medical Resident, Medicine, Michael Reese Hospital & Medical Center 1988 - 1991
  • M.D., Thomas Jefferson University 1988
• 

  Previous Appointments & Affiliations

  • Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
  • Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1996 - 2017
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2013
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2007
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1997 - 2004
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1996 - 1997
• Research
• 

  Selected Grants

  • A randomized double blind studyh of Ruxolitinib or placebo in combination with Regorafenib in subjects with relapsed or refractory metastatic colorectal cancer. awarded by Incyte Corporation 2014 - 2019
  • A Companion study for patient who completed participation in a REGN2810 study awarded by Regeneron Pharmaceuticals, Inc. 2016 - 2018
  • A Phase 2 randomized proff of concept study of Nab-Paclitaxel/Gemcitabine alone and in combination with ACP-196 in subjects with previously untreated metastatic pancreatic cancer. awarded by Acerta Pharma 2015 - 2017
  • Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer awarded by Department of Defense 2016 - 2017
  • Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling awarded by National Institutes of Health 2014 - 2017
  • A randomized double bline phase 3 study of the JAK 1/2 inhibitor Ruxotinib or placebo in conbination with capecitbine in subjects with advanced or metastatic adenocarcinoma of the pancreas awarded by Incyte Corporation 2014 - 2017
  • The prevalence of MET gene amplification in metastatic colorectal cancer awarded by Amgen, Inc. 2014 - 2016
  • Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity awarded by National Institutes of Health 2006 - 2012
  • Wound Angiogenesis as a Biomarker for Tumor Angiogenesis awarded by National Institutes of Health 2006 - 2011
  • Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
  • Partner-Assisted Emotional Disclosure for GI Cancer awarded by National Institutes of Health 2004 - 2008
  • Does NO mediate clinical anti-VEGF vascular effects awarded by National Institutes of Health 2003 - 2006
  • New Clinical Biomarker for Cancer--Wound Angiogenesis awarded by National Institutes of Health 2000 - 2006
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Kollmannsberger, Christian, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L. Reckamp, et al. “Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.” Target Oncol 18, no. 1 (January 2023): 105–18. https://doi.org/10.1007/s11523-022-00931-9.
       Full Text  Link to Item
    • Franko, Jan, Jun Yin, Richard A. Adams, John Zalcberg, Jack Fiskum, Eric Van Cutsem, Richard M. Goldberg, et al. “Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.” Eur J Cancer 174 (October 2022): 142–52. https://doi.org/10.1016/j.ejca.2022.07.021.
       Full Text  Link to Item
    • Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).” Clin Cancer Res 28, no. 13 (July 1, 2022): 2779–88. https://doi.org/10.1158/1078-0432.CCR-21-2389.
       Full Text  Link to Item
    • Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).” Clin Cancer Res 28, no. 13 (July 1, 2022): 2771–78. https://doi.org/10.1158/1078-0432.CCR-21-2386.
       Full Text  Link to Item
    • Yaung, S. J., C. Ju, S. Gattam, A. Nicholas, N. Sommer, J. C. Bendell, H. I. Hurwitz, et al. “Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.” Cancers 14, no. 9 (May 1, 2022). https://doi.org/10.3390/cancers14092240.
       Full Text
    • Mettu, Niharika B., Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, et al. “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.” Jama Netw Open 5, no. 2 (February 1, 2022): e2149040. https://doi.org/10.1001/jamanetworkopen.2021.49040.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, et al. “Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.” Oncologist 26, no. 6 (June 2021): 465-e917. https://doi.org/10.1002/onco.13678.
       Full Text  Link to Item
    • Lopes, Guilherme S., Christophe Tournigand, Curtis L. Olswold, Romain Cohen, Emmanuelle Kempf, Leonard Saltz, Richard M. Goldberg, et al. “Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials.” Clin Trials 18, no. 1 (February 2021): 51–60. https://doi.org/10.1177/1740774520959313.
       Full Text  Link to Item
    • Yin, J., S. Dawood, R. Cohen, J. Meyers, J. Zalcberg, T. Yoshino, M. Seymour, et al. “Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.” Therapeutic Advances in Medical Oncology 13 (January 1, 2021). https://doi.org/10.1177/17588359211020547.
       Full Text
    • Cremolini, Chiara, Carlotta Antoniotti, Alexander Stein, Johanna Bendell, Thomas Gruenberger, Daniele Rossini, Gianluca Masi, et al. “Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.” J Clin Oncol, August 20, 2020, JCO2001225. https://doi.org/10.1200/JCO.20.01225.
       Full Text  Link to Item
    • Max Ma, Xiaoju, Johanna C. Bendell, Herbert I. Hurwitz, Christine Ju, John J. Lee, Alex Lovejoy, Christoph Mancao, et al. “Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.” Clin Cancer Res 26, no. 15 (August 1, 2020): 4010–17. https://doi.org/10.1158/1078-0432.CCR-19-1209.
       Full Text  Link to Item
    • Garcia, Josep, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L. Coleman, Regula Deurloo, and Olivier L. Chinot. “Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.” Cancer Treat Rev 86 (June 2020): 102017. https://doi.org/10.1016/j.ctrv.2020.102017.
       Full Text  Link to Item
    • Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
       Full Text  Link to Item
    • Bendell, Johanna C., Tamara Sauri, Antonio Cubillo Gracián, Rafael Alvarez, Carlos López-López, Pilar García-Alfonso, Maen Hussein, et al. “The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).” Oncologist, September 30, 2019. https://doi.org/10.1634/theoncologist.2019-0291.
       Full Text  Link to Item
    • Burzykowski, Tomasz, Elisabeth Coart, Everardo D. Saad, Qian Shi, Dirkje W. Sommeijer, Carsten Bokemeyer, Eduardo Díaz-Rubio, et al. “Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.” Jama Netw Open 2, no. 9 (September 4, 2019): e1911750. https://doi.org/10.1001/jamanetworkopen.2019.11750.
       Full Text  Link to Item
    • Coker, Shodeinde A., Herbert I. Hurwitz, Sunil Sharma, Ding Wang, Pierre Jordaan, Juan Pablo Zarate, and Lionel D. Lewis. “The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.” Cancer Chemother Pharmacol 84, no. 2 (August 2019): 383–92. https://doi.org/10.1007/s00280-019-03880-9.
       Full Text  Link to Item
    • Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz-Josef Lenz, Howard S. Hochster, et al. “Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).” Oncologist 24, no. 7 (July 2019): 921–32. https://doi.org/10.1634/theoncologist.2018-0344.
       Full Text  Link to Item
    • Meric-Bernstam, Funda, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R. McWilliams, Marwan Fakih, Ari VanderWalde, Charles Swanton, et al. “Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.” Lancet Oncol 20, no. 4 (April 2019): 518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.
       Full Text  Link to Item
    • Loupakis, Fotios, Herbert I. Hurwitz, Leonard Saltz, Dirk Arnold, Axel Grothey, Quynh Lan Nguyen, Stuart Osborne, Jonathan Talbot, Stefanie Srock, and Heinz-Josef Lenz. “Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.” Br J Cancer 119, no. 12 (December 2018): 1451–55. https://doi.org/10.1038/s41416-018-0304-6.
       Full Text  Link to Item
    • Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients.” Sci Rep 8, no. 1 (November 5, 2018): 16332. https://doi.org/10.1038/s41598-018-34506-4.
       Full Text  Link to Item
    • Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.” Mol Cancer Ther 17, no. 10 (October 2018): 2248–56. https://doi.org/10.1158/1535-7163.MCT-17-0916.
       Full Text  Link to Item
    • Hainsworth, John D., Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard Burris, et al. “Reply to J.J. Tao et al.” J Clin Oncol 36, no. 23 (August 10, 2018): 2451. https://doi.org/10.1200/JCO.2018.78.6392.
       Full Text  Link to Item
    • Hurwitz, Herbert, Eric Van Cutsem, Johanna Bendell, Manuel Hidalgo, Chung-Pin Li, Marcelo Garrido Salvo, Teresa Macarulla, et al. “Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.” Invest New Drugs 36, no. 4 (August 2018): 683–95. https://doi.org/10.1007/s10637-018-0580-2.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text  Link to Item
    • Sjoquist, Katrin M., Lindsay A. Renfro, R John Simes, Niall C. Tebbutt, Stephen Clarke, Matthew T. Seymour, Richard Adams, et al. “Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.” J Natl Cancer Inst 110, no. 6 (June 1, 2018): 638–48. https://doi.org/10.1093/jnci/djx253.
       Full Text  Link to Item
    • Siena, S., A. Sartore-Bianchi, S. Marsoni, H. I. Hurwitz, S. J. McCall, F. Penault-Llorca, S. Srock, A. Bardelli, and L. Trusolino. “Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.” Ann Oncol 29, no. 5 (May 1, 2018): 1108–19. https://doi.org/10.1093/annonc/mdy100.
       Full Text  Link to Item
    • Duan, Bensong, Jiangfeng Hu, Hongliang Liu, Yanru Wang, Hongyu Li, Shun Liu, Jichun Xie, et al. “Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.” Int J Cancer 142, no. 7 (April 1, 2018): 1322–31. https://doi.org/10.1002/ijc.31171.
       Full Text  Open Access Copy  Link to Item
    • Seligmann, Jenny F., Ace J. Hatch, Susan D. Richman, Faye Elliott, Bart Jacobs, Sarah Brown, Herbert Hurwitz, et al. “Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.” Jama Oncol 4, no. 4 (April 1, 2018): 564–68. https://doi.org/10.1001/jamaoncol.2017.3168.
       Full Text  Link to Item
    • Chan, Emily, E Gabriela Chiorean, Peter J. O’Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Diane Potvin, Richard Chao, and Herbert Hurwitz. “Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.” Cancer Chemother Pharmacol 81, no. 2 (February 2018): 355–64. https://doi.org/10.1007/s00280-017-3494-3.
       Full Text  Link to Item
    • Grothey, Axel, Jonathan R. Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz, John L. Marshall, Howard Safran, Michael J. Guarino, et al. “A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.” Clin Cancer Res 24, no. 2 (January 15, 2018): 316–25. https://doi.org/10.1158/1078-0432.CCR-17-1558.
       Full Text  Link to Item
    • Bauer, Todd M., Manish R. Patel, Andres Forero-Torres, Thomas J. George, Albert Assad, Yining Du, and Herbert Hurwitz. “A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.” Onco Targets Ther 11 (2018): 2399–2407. https://doi.org/10.2147/OTT.S157331.
       Full Text  Link to Item
    • Chen, Daniel S., and Herbert Hurwitz. “Combinations of Bevacizumab With Cancer Immunotherapy.” Cancer J 24, no. 4 (2018): 193–204. https://doi.org/10.1097/PPO.0000000000000327.
       Full Text  Link to Item
    • Ronald, James, Andrew B. Nixon, Daniele Marin, Rajan T. Gupta, Gemini Janas, Willa Chen, Paul V. Suhocki, et al. “Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.” Radiology 285, no. 1 (October 2017): 311–18. https://doi.org/10.1148/radiol.2017162555.
       Full Text  Link to Item
    • Renfro, Lindsay A., Richard M. Goldberg, Axel Grothey, Alberto Sobrero, Richard Adams, Matthew T. Seymour, Volker Heinemann, et al. “Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.” J Clin Oncol 35, no. 17 (June 10, 2017): 1929–37. https://doi.org/10.1200/JCO.2016.71.5771.
       Full Text  Link to Item
    • Argilés, G., J. Saro, N. H. Segal, I. Melero, W. Ros, A. Marabelle, M. E. Rodriguez, et al. “Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).” Ann Oncol 28 Suppl 3 (June 2017): iii151. https://doi.org/10.1093/annonc/mdx302.003.
       Full Text  Link to Item
    • García-Carbonero, Rocío, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall Tebbutt, Fadi Braiteh, et al. “Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.” Oncologist 22, no. 4 (April 2017): 375-e30. https://doi.org/10.1634/theoncologist.2016-0133.
       Full Text  Link to Item
    • Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.
       Full Text  Link to Item
    • Langman, Eun L., Paul V. Suhocki, Herbert I. Hurwitz, Michael A. Morse, Rebecca A. Burbridge, Tony P. Smith, and Charles Y. Kim. “Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.” J Gastrointest Oncol 7, no. 6 (December 2016): 875–81. https://doi.org/10.21037/jgo.2016.06.13.
       Full Text  Link to Item
    • Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, J Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, et al. “Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Cancer Med 5, no. 9 (September 2016): 2249–60. https://doi.org/10.1002/cam4.806.
       Full Text  Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
       Full Text  Open Access Copy  Link to Item
    • Hurwitz, Herbert I. “HER2 testing in metastatic colorectal cancer: ready for prime time?” Clin Adv Hematol Oncol 14, no. 4 (April 2016): 235–37.
       Link to Item
    • Renfro, Lindsay A., Fotios Loupakis, Richard A. Adams, Matthew T. Seymour, Volker Heinemann, Hans-Joachim Schmoll, Jean-Yves Douillard, et al. “Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.” J Clin Oncol 34, no. 2 (January 10, 2016): 144–50. https://doi.org/10.1200/JCO.2015.61.6441.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, Johanna C. Bendell, J Thaddeus Beck, Seaborn M. Wade, John J. Nemunaitis, et al. “Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.” J Clin Oncol 33, no. 34 (December 1, 2015): 4039–47. https://doi.org/10.1200/JCO.2015.61.4578.
       Full Text  Link to Item
    • Jia, Jingquan, Andrew E. Dellinger, Eric S. Weiss, Anuradha Bulusu, Christel Rushing, Haiyan Li, Leigh A. Howard, et al. “Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.” Clin Cancer Res 21, no. 15 (August 1, 2015): 3442–52. https://doi.org/10.1158/1078-0432.CCR-14-2819.
       Full Text  Link to Item
    • Chiorean, E. G., H. I. Hurwitz, R. B. Cohen, J. D. Schwartz, R. P. Dalal, F. E. Fox, L. Gao, and C. J. Sweeney. “Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.” Ann Oncol 26, no. 6 (June 2015): 1230–37. https://doi.org/10.1093/annonc/mdv144.
       Full Text  Link to Item
    • Reichardt, Peter, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S. Rosen, Beatrice Seddon, Suayib Yalcin, et al. “Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.” Cancer 121, no. 9 (May 1, 2015): 1405–13. https://doi.org/10.1002/cncr.29220.
       Full Text  Link to Item
    • Tebbutt, Niall, Dusan Kotasek, Howard A. Burris, Lee S. Schwartzberg, Herbert Hurwitz, Joe Stephenson, Douglas J. Warner, Lisa Chen, Cheng-Pang Hsu, and David Goldstein. “Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.” Cancer Chemother Pharmacol 75, no. 5 (May 2015): 993–1004. https://doi.org/10.1007/s00280-015-2694-y.
       Full Text  Link to Item
    • Meadows, Kellen L., Christel Rushing, Wanda Honeycutt, Kenneth Latta, Leigh Howard, Christy A. Arrowood, Donna Niedzwiecki, and Herbert I. Hurwitz. “Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.” Support Care Cancer 23, no. 5 (May 2015): 1311–19. https://doi.org/10.1007/s00520-014-2465-z.
       Full Text  Link to Item
    • Hurwitz, Herbert I., David C. Smith, Henry C. Pitot, Jeffrey M. Brill, Rashmi Chugh, Elisabeth Rouits, Joseph Rubin, et al. “Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.” Cancer Chemother Pharmacol 75, no. 4 (April 2015): 851–59. https://doi.org/10.1007/s00280-015-2709-8.
       Full Text  Link to Item
    • Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, et al. “Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.” Mol Cancer Ther 14, no. 4 (April 2015): 1048–56. https://doi.org/10.1158/1535-7163.MCT-14-0923-T.
       Full Text  Link to Item
    • Cushman, Stephanie M., Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon. “Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Clin Cancer Res 21, no. 5 (March 1, 2015): 1078–86. https://doi.org/10.1158/1078-0432.CCR-14-2313.
       Full Text  Link to Item
    • Loupakis, Fotios, Dongyun Yang, Linda Yau, Shibao Feng, Chiara Cremolini, Wu Zhang, Martin K. H. Maus, et al. “Primary tumor location as a prognostic factor in metastatic colorectal cancer.” J Natl Cancer Inst 107, no. 3 (March 2015). https://doi.org/10.1093/jnci/dju427.
       Full Text  Link to Item
    • Rushing, Christel, Anuradha Bulusu, Herbert I. Hurwitz, Andrew B. Nixon, and Herbert Pang. “A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.” Comput Biol Med 57 (February 2015): 123–29. https://doi.org/10.1016/j.compbiomed.2014.11.015.
       Full Text  Link to Item
    • Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.” Cancer Chemother Pharmacol 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.
       Full Text  Link to Item
    • Hurwitz, H. I., D. C. Smith, H. C. Pitot, J. M. Brill, R. Chugh, E. Rouits, J. Rubin, et al. “Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study.” Cancer Chemotherapy and Pharmacology 75, no. 4 (January 1, 2015): 851–59. https://doi.org/10.1007/s00280-015-2709-8.
       Full Text
    • Shi, Qian, Aimery de Gramont, Axel Grothey, John Zalcberg, Benoist Chibaudel, Hans-Joachim Schmoll, Matthew T. Seymour, et al. “Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.” J Clin Oncol 33, no. 1 (January 1, 2015): 22–28. https://doi.org/10.1200/JCO.2014.56.5887.
       Full Text  Link to Item
    • Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.” Cancer J 21, no. 4 (2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.
       Full Text  Link to Item
    • Pili, Roberto, Michael Carducci, Peter Brown, and Herbert Hurwitz. “An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.” Invest New Drugs 32, no. 6 (December 2014): 1258–68. https://doi.org/10.1007/s10637-014-0147-9.
       Full Text  Link to Item
    • Secord, Angeles Alvarez, Andrew B. Nixon, and Herbert I. Hurwitz. “The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.” Gynecol Oncol 135, no. 2 (November 2014): 349–58. https://doi.org/10.1016/j.ygyno.2014.08.033.
       Full Text  Link to Item
    • Clarke, J. M., H. I. Hurwitz, and F. Rangwala. “Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.” Cancer Treat Rev 40, no. 9 (October 2014): 1065–72. https://doi.org/10.1016/j.ctrv.2014.07.001.
       Full Text  Link to Item
    • Cleary, James M., Caio Max S Rocha Lima, Herbert I. Hurwitz, Alberto J. Montero, Catherine Franklin, Jianning Yang, Alison Graham, et al. “A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.” Invest New Drugs 32, no. 5 (October 2014): 937–45. https://doi.org/10.1007/s10637-014-0110-9.
       Full Text  Link to Item
    • Liu, Yingmiao, Hongyu Tian, Gerard C. Blobe, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.” Invest New Drugs 32, no. 5 (October 2014): 851–59. https://doi.org/10.1007/s10637-014-0129-y.
       Full Text  Link to Item
    • Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.
       Full Text  Link to Item
    • Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.
       Full Text  Link to Item
    • Grothey, Axel, E Dawn Flick, Allen L. Cohn, Tanios S. Bekaii-Saab, Johanna C. Bendell, Mark Kozloff, Nancy Roach, Yong Mun, Susan Fish, and Herbert I. Hurwitz. “Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.” Pharmacoepidemiol Drug Saf 23, no. 7 (July 2014): 726–34. https://doi.org/10.1002/pds.3633.
       Full Text  Link to Item
    • Hurwitz, H., N. Uppal, S. A. Wagner, J. Bendell, B. J. Thaddeus, S. Wade, J. Nemunaitis, et al. “Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial.” Annals of Oncology 25 (June 1, 2014): ii115. https://doi.org/10.1093/annonc/mdu193.26.
       Full Text
    • Hurwitz, H. I., T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, M. Kozloff, N. Roach, Y. Mun, et al. “Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.” Clin Oncol (R Coll Radiol) 26, no. 6 (June 2014): 323–32. https://doi.org/10.1016/j.clon.2014.03.001.
       Full Text  Link to Item
    • Liu, Yingmiao, Mark D. Starr, John C. Brady, Andrew Dellinger, Herbert Pang, Bonne Adams, Charles P. Theuer, Nam Y. Lee, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.” Cancer Med 3, no. 3 (June 2014): 580–91. https://doi.org/10.1002/cam4.207.
       Full Text  Link to Item
    • Lane, Whitney O., Rex C. Bentley, Herbert I. Hurwitz, Leigh A. Howard, Thomas J. Polascik, Mark R. Anderson, and Dan G. Blazer. “Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report.” Jop 15, no. 3 (May 27, 2014): 266–68. https://doi.org/10.6092/1590-8577/2407.
       Full Text  Link to Item
    • Younis, Islam R., Daniel J. George, Terence J. McManus, Herbert Hurwitz, Patricia Creel, Andrew J. Armstrong, Jing Jie Yu, et al. “Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.” Cancer Chemother Pharmacol 73, no. 5 (May 2014): 991–97. https://doi.org/10.1007/s00280-014-2432-x.
       Full Text  Link to Item
    • Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.
       Full Text  Link to Item
    • Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, et al. “Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.” Clin Cancer Res 20, no. 2 (January 15, 2014): 480–89. https://doi.org/10.1158/1078-0432.CCR-13-1840.
       Full Text  Link to Item
    • Pili, R., M. Carducci, P. Brown, and H. Hurwitz. “An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.” Investigational New Drugs 32, no. 6 (2014): 1258–68. https://doi.org/10.1007/s10637-014-0147-9.
       Full Text
    • Strickler, J. H., and H. I. Hurwitz. “Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?” Current Oncology Reports 16, no. 1 (2014): 1–8.
    • Strickler, John H., and Herbert I. Hurwitz. “Palliative treatment of metastatic colorectal cancer: what is the optimal approach?” Curr Oncol Rep 16, no. 1 (2014): 363. https://doi.org/10.1007/s11912-013-0363-z.
       Full Text  Link to Item
    • Nixon, Andrew B., Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz, and Herbert I. Alliance for Clinical Trials In Oncology. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).” Clin Cancer Res 19, no. 24 (December 15, 2013): 6957–66. https://doi.org/10.1158/1078-0432.CCR-13-0926.
       Full Text  Link to Item
    • Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of immune system inhibitory checkpoints in colorectal cancer.” Current Colorectal Cancer Reports 9, no. 4 (December 1, 2013): 391–97. https://doi.org/10.1007/s11888-013-0184-3.
       Full Text
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Understanding and targeting resistance to anti-angiogenic therapies.” J Gastrointest Oncol 4, no. 3 (September 2013): 253–63. https://doi.org/10.3978/j.issn.2078-6891.2013.036.
       Full Text  Link to Item
    • Mettu, Niharika B., Herbert Hurwitz, and David S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer.” Oncology (Williston Park) 27, no. 8 (August 2013): 746–54.
       Link to Item
    • Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab.” Expert Opin Biol Ther 13, no. 8 (August 2013): 1187–96. https://doi.org/10.1517/14712598.2013.810717.
       Full Text  Link to Item
    • Jonge, Maja J. A. de, Paul Hamberg, Jaap Verweij, Shawna Savage, A Benjamin Suttle, Jeffrey Hodge, Thangam Arumugham, Lini N. Pandite, and Herbert I. Hurwitz. “Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.” Invest New Drugs 31, no. 3 (June 2013): 751–59. https://doi.org/10.1007/s10637-012-9885-8.
       Full Text  Link to Item
    • Rosen, Lee S., Lara Lipton, Timothy J. Price, Neil D. Belman, Ralph V. Boccia, Herbert I. Hurwitz, Joe J. Stephenson, et al. “The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.” Bmc Cancer 13 (May 16, 2013): 242. https://doi.org/10.1186/1471-2407-13-242.
       Full Text  Link to Item
    • Jia, Jingquan, Alex Starodub, Ian Cushman, Yingmiao Liu, Deborah J. Marshall, Herbert I. Hurwitz, and Andrew B. Nixon. “Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.” Anticancer Drugs 24, no. 3 (March 2013): 237–50. https://doi.org/10.1097/CAD.0b013e32835d29fd.
       Full Text  Link to Item
    • Altomare, Ivy, and Herbert Hurwitz. “Everolimus in colorectal cancer.” Expert Opin Pharmacother 14, no. 4 (March 2013): 505–13. https://doi.org/10.1517/14656566.2013.770473.
       Full Text  Link to Item
    • Mettu, N. B., H. Hurwitz, and D. S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer.” Oncology (United States) 27, no. 8 (January 1, 2013).
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?” Nat Rev Clin Oncol 10, no. 1 (January 2013): 10–11. https://doi.org/10.1038/nrclinonc.2012.197.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Niall C. Tebbutt, Fairooz Kabbinavar, Bruce J. Giantonio, Zhong-Zhen Guan, Lada Mitchell, Daniel Waterkamp, and Josep Tabernero. “Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.” Oncologist 18, no. 9 (2013): 1004–12. https://doi.org/10.1634/theoncologist.2013-0107.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Pamela S. Douglas, John P. Middleton, George W. Sledge, David H. Johnson, David A. Reardon, Dafeng Chen, and Oliver Rosen. “Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.” Oncologist 18, no. 3 (2013): 273–80. https://doi.org/10.1634/theoncologist.2012-0339.
       Full Text  Link to Item
    • Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer.” Current Colorectal Cancer Reports, 2013, 1–7.
    • Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.
       Full Text  Link to Item
    • Weinfurt, Kevin P., Damon M. Seils, Li Lin, Daniel P. Sulmasy, Alan B. Astrow, Herbert I. Hurwitz, Roger B. Cohen, and Neal J. Meropol. “Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?” J Clin Oncol 30, no. 35 (December 10, 2012): 4396–4400. https://doi.org/10.1200/JCO.2011.40.6587.
       Full Text  Link to Item
    • Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.” Cold Spring Harbor Perspectives in Biology 4, no. 11 (November 1, 2012).
    • Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.” Cold Spring Harbor Perspectives in Medicine 2, no. 10 (October 1, 2012).
    • Meadows, Kellen L., and Herbert I. Hurwitz. “Anti-VEGF therapies in the clinic.” Cold Spring Harb Perspect Med 2, no. 10 (October 1, 2012). https://doi.org/10.1101/cshperspect.a006577.
       Full Text  Link to Item
    • Rosen, Lee S., Herbert I. Hurwitz, Michael K. Wong, Jonathan Goldman, David S. Mendelson, William D. Figg, Shawn Spencer, et al. “A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.” Clin Cancer Res 18, no. 17 (September 1, 2012): 4820–29. https://doi.org/10.1158/1078-0432.CCR-12-0098.
       Full Text  Link to Item
    • Porter, Laura S., Francis J. Keefe, Donald H. Baucom, Herbert Hurwitz, Barry Moser, Emily Patterson, and Hong Jin Kim. “Partner-assisted emotional disclosure for patients with GI cancer: 8-week follow-up and processes associated with change.” Support Care Cancer 20, no. 8 (August 2012): 1755–62. https://doi.org/10.1007/s00520-011-1272-z.
       Full Text  Link to Item
    • Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.
       Full Text  Link to Item
    • Papalezova, Katia T., Douglas S. Tyler, Dan G. Blazer, Bryan M. Clary, Brian G. Czito, Herbert I. Hurwitz, Hope E. Uronis, Theodore N. Pappas, Christopher G. Willett, and Rebekah R. White. “Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?” J Surg Oncol 106, no. 1 (July 1, 2012): 111–18. https://doi.org/10.1002/jso.23044.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
       Full Text  Link to Item
    • Peer, Cody J., Terence J. McManus, Herbert I. Hurwitz, and William P. Petros. “Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.” J Chromatogr B Analyt Technol Biomed Life Sci 898 (June 1, 2012): 32–37. https://doi.org/10.1016/j.jchromb.2012.04.010.
       Full Text  Link to Item
    • Demetri, George D., Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, et al. “Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.” Clin Cancer Res 18, no. 11 (June 1, 2012): 3170–79. https://doi.org/10.1158/1078-0432.CCR-11-3005.
       Full Text  Link to Item
    • Palta, Manisha, Pretesh Patel, Gloria Broadwater, Christopher Willett, Joseph Pepek, Douglas Tyler, S Yousuf Zafar, et al. “Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.” Ann Surg Oncol 19, no. 5 (May 2012): 1535–40. https://doi.org/10.1245/s10434-011-2117-1.
       Full Text  Link to Item
    • Hurwitz, Herbert I., and Gary H. Lyman. “Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?” J Clin Oncol 30, no. 6 (February 20, 2012): 580–81. https://doi.org/10.1200/JCO.2011.40.7031.
       Full Text  Link to Item
    • Innocenti, Federico, Kouros Owzar, Nancy L. Cox, Patrick Evans, Michiaki Kubo, Hitoshi Zembutsu, Chen Jiang, et al. “A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.” Clin Cancer Res 18, no. 2 (January 15, 2012): 577–84. https://doi.org/10.1158/1078-0432.CCR-11-1387.
       Full Text  Link to Item
    • Bendell, Johanna C., Tanios S. Bekaii-Saab, Allen L. Cohn, Herbert I. Hurwitz, Mark Kozloff, Haluk Tezcan, Nancy Roach, et al. “Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.” Oncologist 17, no. 12 (2012): 1486–95. https://doi.org/10.1634/theoncologist.2012-0190.
       Full Text  Link to Item
    • Hurwitz, Herbert, Edith P. Mitchell, Thomas Cartwright, Ambrose Kwok, Sylvia Hu, Edward McKenna, and Yehuda Z. Patt. “A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).” Oncologist 17, no. 7 (2012): 937–46. https://doi.org/10.1634/theoncologist.2012-0071.
       Full Text  Link to Item
    • Strickler, John H., and Herbert I. Hurwitz. “Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.” Oncologist 17, no. 1 (2012): 9–10. https://doi.org/10.1634/theoncologist.2011-0358.
       Full Text  Link to Item
    • Strickler, John H., and Herbert I. Hurwitz. “Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.” Oncologist 17, no. 4 (2012): 513–24. https://doi.org/10.1634/theoncologist.2012-0003.
       Full Text  Link to Item
    • LoRusso, Patricia, Geoffrey I. Shapiro, Herbert Hurwitz, Mary Jo Pilat, Janice Chemidlin, Georgia Kollia, Shariq Syed, Bruce Fischer, and Eric Masson. “Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.” Cancer Chemother Pharmacol 68, no. 6 (December 2011): 1377–85. https://doi.org/10.1007/s00280-011-1603-2.
       Full Text  Link to Item
    • Ghafoori, A Paiman, John W. Nelson, Christopher G. Willett, Junzo Chino, Douglas S. Tyler, Herbert I. Hurwitz, Hope E. Uronis, Michael A. Morse, Robert W. Clough, and Brian G. Czito. “Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.” Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 654–59. https://doi.org/10.1016/j.ijrobp.2010.06.018.
       Full Text  Link to Item
    • Wong, Nan Soon, Kellen L. Meadows, Lee S. Rosen, Alex A. Adjei, Scott H. Kaufmann, Michael A. Morse, William P. Petros, et al. “A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.” Cancer Invest 29, no. 9 (November 2011): 617–25. https://doi.org/10.3109/07357907.2011.621912.
       Full Text  Link to Item
    • Lyman, G. H., H. I. Hurwitz, F. Sirzén, and U. P. Rohr. “Reply to S. Hapani et al.” Journal of Clinical Oncology 29, no. 25 (September 1, 2011): 3490–91. https://doi.org/10.1200/JCO.2011.36.5692.
       Full Text
    • Wong, Nan Soon, Nishan H. Fernando, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe, Wanda Honeycutt, Herbert Pang, and Herbert I. Hurwitz. “A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.” Clin Colorectal Cancer 10, no. 3 (September 2011): 210–16. https://doi.org/10.1016/j.clcc.2011.03.018.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Leonard B. Saltz, Eric Van Cutsem, James Cassidy, Jonas Wiedemann, Florin Sirzén, Gary H. Lyman, and Ulrich-Peter Rohr. “Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.” J Clin Oncol 29, no. 13 (May 1, 2011): 1757–64. https://doi.org/10.1200/JCO.2010.32.3220.
       Full Text  Link to Item
    • Bullock, Karen E., William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S Yousuf Zafar, et al. “A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465–74. https://doi.org/10.1007/s00280-010-1507-6.
       Full Text  Link to Item
    • Castaneda, Carlos, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, and Herbert I. Hurwitz. “Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 455–63. https://doi.org/10.1007/s00280-010-1488-5.
       Full Text  Link to Item
    • Leighl, N. B., J. Bennouna, J. Yi, N. Moore, J. Hambleton, and H. Hurwitz. “Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.” Br J Cancer 104, no. 3 (February 1, 2011): 413–18. https://doi.org/10.1038/sj.bjc.6606074.
       Full Text  Link to Item
    • Miles, David, Nadia Harbeck, Bernard Escudier, Herbert Hurwitz, Leonard Saltz, Eric Van Cutsem, Jim Cassidy, Barbara Mueller, and Florin Sirzén. “Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.” J Clin Oncol 29, no. 1 (January 1, 2011): 83–88. https://doi.org/10.1200/JCO.2010.30.2794.
       Full Text  Link to Item
    • Altomare, Ivy, Johanna C. Bendell, Karen E. Bullock, Hope E. Uronis, Michael A. Morse, S David Hsu, S Yousuf Zafar, et al. “A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.” Oncologist 16, no. 8 (2011): 1131–37. https://doi.org/10.1634/theoncologist.2011-0078.
       Full Text  Link to Item
    • Wong, Nan Soon, Nishan H. Fernando, Andrew B. Nixon, Stephanie Cushman, Mebea Aklilu, Johanna C. Bendell, Michael A. Morse, et al. “A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.” Anticancer Res 31, no. 1 (January 2011): 255–61.
       Link to Item
    • Baselga, José, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, et al. “Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.” Clin Cancer Res 16, no. 19 (October 1, 2010): 4876–83. https://doi.org/10.1158/1078-0432.CCR-10-0748.
       Full Text  Link to Item
    • Kindler, Hedy Lee, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert Hurwitz, Federico Innocenti, et al. “Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).” J Clin Oncol 28, no. 22 (August 1, 2010): 3617–22. https://doi.org/10.1200/JCO.2010.28.1386.
       Full Text  Link to Item
    • Cassidy, James, Leonard B. Saltz, Bruce J. Giantonio, Fairooz F. Kabbinavar, Herbert I. Hurwitz, and Ulrich-Peter Rohr. “Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.” J Cancer Res Clin Oncol 136, no. 5 (May 2010): 737–43. https://doi.org/10.1007/s00432-009-0712-3.
       Full Text  Link to Item
    • Advani, Ranjana H., Herbert I. Hurwitz, Michael S. Gordon, Scot W. Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, et al. “Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.” Clin Cancer Res 16, no. 7 (April 1, 2010): 2167–75. https://doi.org/10.1158/1078-0432.CCR-09-2236.
       Full Text  Link to Item
    • Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Andrew B. Nixon, William P. Petros, Justin Favaro, Nishan H. Fernando, Michael A. Morse, Gerard C. Blobe, and Herbert I. Hurwitz. “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” Anticancer Res 30, no. 4 (April 2010): 1251–56.
       Link to Item
    • Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Gerald C. Blobe, Michael A. Morse, Nishan H. Fernando, Jon P. Gockerman, William P. Petros, and Herbert I. Hurwitz. “Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.” Anticancer Res 29, no. 12 (December 2009): 5149–53.
       Link to Item
    • Porter, Laura S., Francis J. Keefe, Donald H. Baucom, Herbert Hurwitz, Barry Moser, Emily Patterson, and Hong Jin Kim. “Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial.” Cancer 115, no. 18 Suppl (September 15, 2009): 4326–38. https://doi.org/10.1002/cncr.24578.
       Full Text  Link to Item
    • Facemire, Carie S., Andrew B. Nixon, Robert Griffiths, Herbert Hurwitz, and Thomas M. Coffman. “Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.” Hypertension 54, no. 3 (September 2009): 652–58. https://doi.org/10.1161/HYPERTENSIONAHA.109.129973.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Afshin Dowlati, Shermini Saini, Shawna Savage, A Benjamin Suttle, Diana M. Gibson, Jeffrey P. Hodge, Elmar M. Merkle, and Lini Pandite. “Phase I trial of pazopanib in patients with advanced cancer.” Clin Cancer Res 15, no. 12 (June 15, 2009): 4220–27. https://doi.org/10.1158/1078-0432.CCR-08-2740.
       Full Text  Link to Item
    • Kabbinavar, Fairooz F., Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, and Oliver Rosen. “Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.” J Clin Oncol 27, no. 2 (January 10, 2009): 199–205. https://doi.org/10.1200/JCO.2008.17.7931.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Jing Yi, William Ince, William F. Novotny, and Oliver Rosen. “The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.” Oncologist 14, no. 1 (January 2009): 22–28. https://doi.org/10.1634/theoncologist.2008-0213.
       Full Text  Link to Item
    • Kass, Nancy E., Jeremy Sugarman, Amy M. Medley, Linda A. Fogarty, Holly A. Taylor, Christopher K. Daugherty, Mark R. Emerson, et al. “An intervention to improve cancer patients' understanding of early-phase clinical trials.” Irb 31, no. 3 (2009): 1–10.
       Link to Item
    • Nelson, John W., A Paiman Ghafoori, Christopher G. Willett, Douglas S. Tyler, Theodore N. Pappas, Bryan M. Clary, Herbert I. Hurwitz, et al. “Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.” Int J Radiat Oncol Biol Phys 73, no. 1 (January 1, 2009): 148–53. https://doi.org/10.1016/j.ijrobp.2008.07.008.
       Full Text  Link to Item
    • Reddy, Srinevas K., Gloria Broadwater, Donna Niedzwiecki, Andrew S. Barbas, Herbert I. Hurwitz, Johanna C. Bendell, Michael A. Morse, and Bryan M. Clary. “Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.” J Gastrointest Surg 13, no. 1 (January 2009): 74–84. https://doi.org/10.1007/s11605-008-0617-5.
       Full Text  Link to Item
    • Armstrong, Andrew J., Patricia Creel, James Turnbull, Cassandra Moore, Tracy A. Jaffe, Sherri Haley, William Petros, et al. “A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.” Clin Cancer Res 14, no. 19 (October 1, 2008): 6270–76. https://doi.org/10.1158/1078-0432.CCR-08-1085.
       Full Text  Link to Item
    • Kabbinavar, Fairooz F., Joel F. Wallace, Eric Holmgren, Jing Yi, David Cella, Kathleen J. Yost, and Herbert I. Hurwitz. “Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.” Oncologist 13, no. 9 (September 2008): 1021–29. https://doi.org/10.1634/theoncologist.2008-0003.
       Full Text  Link to Item
    • Osada, Takuya, Gabriel Chong, Robert Tansik, Timothy Hong, Neil Spector, Rakesh Kumar, Herbert I. Hurwitz, et al. “The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.” Cancer Immunol Immunother 57, no. 8 (August 2008): 1115–24. https://doi.org/10.1007/s00262-007-0441-x.
       Full Text  Link to Item
    • Scappaticci, F. A., J. R. Skillings, S. N. Holden, H. P. Gerber, K. Miller, F. Kabbinavar, E. Bergsland, et al. “Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab (Journal of the National Cancer Institute (2007) 99 (1232-1239)).” Journal of the National Cancer Institute 100, no. 9 (May 1, 2008): 685. https://doi.org/10.1093/jnci/djn126.
       Full Text
    • Czito, Brian G., Darrel P. Cohen, Chris R. Kelsey, A Craig Lockhart, Johanna C. Bendell, Christopher G. Willett, William P. Petros, Thomas A. D’Amico, Roxanne Truax, and Herbert I. Hurwitz. “A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.” Int J Radiat Oncol Biol Phys 70, no. 4 (March 15, 2008): 1066–72. https://doi.org/10.1016/j.ijrobp.2007.07.2347.
       Full Text  Link to Item
    • Grothey, Axel, Eric E. Hedrick, Robert D. Mass, Somnath Sarkar, Sam Suzuki, Ramesh K. Ramanathan, Herbert I. Hurwitz, Richard M. Goldberg, and Daniel J. Sargent. “Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.” J Clin Oncol 26, no. 2 (January 10, 2008): 183–89. https://doi.org/10.1200/JCO.2007.13.8099.
       Full Text  Link to Item
    • Kabbinavar, Fairooz, Cornelia Irl, Alfredo Zurlo, and Herbert Hurwitz. “Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.” Oncology 75, no. 3–4 (2008): 215–23. https://doi.org/10.1159/000163850.
       Full Text  Link to Item
    • Reddy, Srinevas K., Michael A. Morse, Herbert I. Hurwitz, Johanna C. Bendell, Tong J. Gan, Steven E. Hill, and Bryan M. Clary. “Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.” J Am Coll Surg 206, no. 1 (January 2008): 96–106. https://doi.org/10.1016/j.jamcollsurg.2007.06.290.
       Full Text  Link to Item
    • Kelsey, Chris R., John W. Nelson, Christopher G. Willett, Junzo P. Chino, Robert W. Clough, Johanna C. Bendell, Douglas S. Tyler, et al. “Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.” Int J Radiat Oncol Biol Phys 69, no. 5 (December 1, 2007): 1436–41. https://doi.org/10.1016/j.ijrobp.2007.05.006.
       Full Text  Link to Item
    • Kelsey, Chris R., Junzo P. Chino, Christopher G. Willett, Robert W. Clough, Herbert I. Hurwitz, Michael A. Morse, Johanna C. Bendell, Thomas A. D’Amico, and Brian G. Czito. “Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.” Int J Radiat Oncol Biol Phys 69, no. 3 (November 1, 2007): 770–76. https://doi.org/10.1016/j.ijrobp.2007.03.035.
       Full Text  Link to Item
    • Saltz, Leonard B., Lee S. Rosen, John L. Marshall, Robert J. Belt, Herbert I. Hurwitz, S Gail Eckhardt, Emily K. Bergsland, et al. “Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.” J Clin Oncol 25, no. 30 (October 20, 2007): 4793–99. https://doi.org/10.1200/JCO.2007.12.8637.
       Full Text  Link to Item
    • Scappaticci, Frank A., Jamey R. Skillings, Scott N. Holden, Hans-Peter Gerber, Kathy Miller, Fairooz Kabbinavar, Emily Bergsland, et al. “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.” J Natl Cancer Inst 99, no. 16 (August 15, 2007): 1232–39. https://doi.org/10.1093/jnci/djm086.
       Full Text  Link to Item
    • Zafar, Y., and H. I. Hurwitz. “Monoclonal antibodies to EGFR: What does the future hold?” Oncology 21, no. 8 (July 1, 2007): 976–77.
    • Czito, Brian G., Johanna C. Bendell, Christopher G. Willett, Michael A. Morse, Gerard C. Blobe, Douglas S. Tyler, John Thomas, et al. “Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.” Int J Radiat Oncol Biol Phys 68, no. 2 (June 1, 2007): 472–78. https://doi.org/10.1016/j.ijrobp.2007.02.001.
       Full Text  Link to Item
    • Willett, Christopher G., Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Brian G. Czito, Zeljko Vujaskovic, Gordana Vlahovic, et al. “Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.” Nat Clin Pract Oncol 4, no. 5 (May 2007): 316–21. https://doi.org/10.1038/ncponc0813.
       Full Text  Link to Item
    • Uronis, Hope E., and Herbert I. Hurwitz. “Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?” Nat Clin Pract Oncol 4, no. 4 (April 2007): 214–15. https://doi.org/10.1038/ncponc0748.
       Full Text  Link to Item
    • Czito, Brian G., Chris R. Kelsey, Herbert I. Hurwitz, Chris G. Willett, Michael A. Morse, Gerard C. Blobe, Nishan H. Fernando, et al. “A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.” Int J Radiat Oncol Biol Phys 67, no. 4 (March 15, 2007): 1002–7. https://doi.org/10.1016/j.ijrobp.2006.10.027.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Roger B. Cohen, J Patrick McGovren, Samit Hirawat, William P. Petros, Yutaka Natsumeda, and Tomoko Yoshinari. “A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.” Cancer Chemother Pharmacol 59, no. 1 (January 2007): 139–47. https://doi.org/10.1007/s00280-006-0267-9.
       Full Text  Link to Item
    • Hurwitz, Herbert, and Shermini Saini. “Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.” Semin Oncol 33, no. 5 Suppl 10 (October 2006): S26–34. https://doi.org/10.1053/j.seminoncol.2006.08.001.
       Full Text  Link to Item
    • Abou-Alfa, Ghassan K., Richard Letourneau, Graydon Harker, Manuel Modiano, Herbert Hurwitz, Nerses Simon Tchekmedyian, Kevie Feit, et al. “Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.” J Clin Oncol 24, no. 27 (September 20, 2006): 4441–47. https://doi.org/10.1200/JCO.2006.07.0201.
       Full Text  Link to Item
    • Goldberg, Richard M., Herbert I. Hurwitz, and Charles S. Fuchs. “The role of targeted therapy in the treatment of colorectal cancer.” Clin Adv Hematol Oncol 4, no. 8 Suppl 17 (August 2006): 1–10.
       Link to Item
    • Hurwitz, Herbert I., Wanda Honeycutt, Sherri Haley, and Justin Favaro. “Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.” Clin Colorectal Cancer 6, no. 1 (May 2006): 66–69. https://doi.org/10.3816/CCC.2006.n.023.
       Full Text  Link to Item
    • Czito, Brian G., Christopher G. Willett, Johanna C. Bendell, Michael A. Morse, Douglas S. Tyler, Nishan H. Fernando, Christopher R. Mantyh, et al. “Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.” J Clin Oncol 24, no. 4 (February 1, 2006): 656–62. https://doi.org/10.1200/JCO.2005.04.1749.
       Full Text  Link to Item
    • Czito, Brian G., Timothy J. Hong, Darrel P. Cohen, William P. Petros, Douglas S. Tyler, Theodore N. Pappas, Daohai Yu, et al. “A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.” Cancer Invest 24, no. 1 (February 2006): 9–17. https://doi.org/10.1080/07357900500449454.
       Full Text  Link to Item
    • Jubb, Adrian M., Herbert I. Hurwitz, Wei Bai, Eric B. Holmgren, Patti Tobin, A Steven Guerrero, Fairooz Kabbinavar, et al. “Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.” J Clin Oncol 24, no. 2 (January 10, 2006): 217–27. https://doi.org/10.1200/JCO.2005.01.5388.
       Full Text  Link to Item
    • Goldberg, Richard M., Herbert I. Hurwitz, and Charles S. Fuchs. “Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.” Clin Adv Hematol Oncol 3, no. 12 (December 2005): 1–10.
       Link to Item
    • Ko, Jason, Joel Ross, Hani Awad, Herbert Hurwitz, and Bruce Klitzman. “The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.” J Surg Res 129, no. 2 (December 2005): 251–59. https://doi.org/10.1016/j.jss.2005.05.006.
       Full Text  Link to Item
    • Porter, Laura S., Francis J. Keefe, Herbert Hurwitz, and Michelle Faber. “Disclosure between patients with gastrointestinal cancer and their spouses.” Psychooncology 14, no. 12 (December 2005): 1030–42. https://doi.org/10.1002/pon.915.
       Full Text  Link to Item
    • Porter, Laura S., Francis J. Keefe, Isaac Lipkus, and Herbert Hurwitz. “Ambivalence over emotional expression in patients with gastrointestinal cancer and their caregivers: associations with patient pain and quality of life.” Pain 117, no. 3 (October 2005): 340–48. https://doi.org/10.1016/j.pain.2005.06.021.
       Full Text  Link to Item
    • Scappaticci, Frank A., Louis Fehrenbacher, Thomas Cartwright, John D. Hainsworth, William Heim, Jordan Berlin, Fairooz Kabbinavar, William Novotny, Somnath Sarkar, and Herbert Hurwitz. “Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.” J Surg Oncol 91, no. 3 (September 1, 2005): 173–80. https://doi.org/10.1002/jso.20301.
       Full Text  Link to Item
    • Burris, Howard A., Herbert I. Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O’Neil, Paul K. Marcom, et al. “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.” J Clin Oncol 23, no. 23 (August 10, 2005): 5305–13. https://doi.org/10.1200/JCO.2005.16.584.
       Full Text  Link to Item
    • Holden, S. N., S. G. Eckhardt, R. Basser, R. de Boer, D. Rischin, M. Green, M. A. Rosenthal, C. Wheeler, A. Barge, and H. I. Hurwitz. “Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.” Ann Oncol 16, no. 8 (August 2005): 1391–97. https://doi.org/10.1093/annonc/mdi247.
       Full Text  Link to Item
    • Czito, Brian G., Herbert I. Hurwitz, Robert W. Clough, Douglas S. Tyler, Michael A. Morse, Bryan M. Clary, Theodore N. Pappas, Nishan H. Fernando, and Christopher G. Willett. “Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience.” Int J Radiat Oncol Biol Phys 62, no. 4 (July 15, 2005): 1030–34. https://doi.org/10.1016/j.ijrobp.2004.12.059.
       Full Text  Link to Item
    • Ince, William L., Adrian M. Jubb, Scott N. Holden, Eric B. Holmgren, Patti Tobin, Meera Sridhar, Herbert I. Hurwitz, et al. “Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.” J Natl Cancer Inst 97, no. 13 (July 6, 2005): 981–89. https://doi.org/10.1093/jnci/dji174.
       Full Text  Link to Item
    • Kabbinavar, Fairooz F., Julie Hambleton, Robert D. Mass, Herbert I. Hurwitz, Emily Bergsland, and Somnath Sarkar. “Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.” J Clin Oncol 23, no. 16 (June 1, 2005): 3706–12. https://doi.org/10.1200/JCO.2005.00.232.
       Full Text  Link to Item
    • Hurwitz, Herbert I., Louis Fehrenbacher, John D. Hainsworth, William Heim, Jordan Berlin, Eric Holmgren, Julie Hambleton, William F. Novotny, and Fairooz Kabbinavar. “Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.” J Clin Oncol 23, no. 15 (May 20, 2005): 3502–8. https://doi.org/10.1200/JCO.2005.10.017.
       Full Text  Link to Item
    • Mis, Lydia, Nishan H. Fernando, Hurbert I. Hurwitz, and Michael A. Morse. “Successful desensitization to oxaliplatin.” Ann Pharmacother 39, no. 5 (May 2005): 966–69. https://doi.org/10.1345/aph.1E532.
       Full Text  Link to Item
    • Hurwitz, Herbert. “New combinations in metastatic colorectal cancer: what are our expectations?” Oncologist 10, no. 5 (May 2005): 320–22. https://doi.org/10.1634/theoncologist.10-5-320.
       Full Text  Link to Item
    • Spector, Neil L., Wenle Xia, Howard Burris, Herbert Hurwitz, E Claire Dees, Afshin Dowlati, Bert O’Neil, et al. “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.” J Clin Oncol 23, no. 11 (April 10, 2005): 2502–12. https://doi.org/10.1200/JCO.2005.12.157.
       Full Text  Link to Item
    • White, Rebekah R., H Bill Xie, Marcia R. Gottfried, Brian G. Czito, Herbert I. Hurwitz, Michael A. Morse, Gerald C. Blobe, et al. “Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.” Ann Surg Oncol 12, no. 3 (March 2005): 214–21. https://doi.org/10.1245/ASO.2005.03.105.
       Full Text  Link to Item
    • Collins, Timothy S., and Herbert I. Hurwitz. “Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.” Semin Oncol 32, no. 1 (February 2005): 61–68. https://doi.org/10.1053/j.seminoncol.2004.09.026.
       Full Text  Link to Item
    • Herbst, Roy S., Pat LoRusso, Takeshi Isobe, and Herbert I. Hurwitz. “Angiogenesis pathway inhibitors.” Cancer Chemother Biol Response Modif 22 (2005): 225–45. https://doi.org/10.1016/s0921-4410(04)22010-5.
       Full Text  Link to Item
    • Hurwitz, Herbert, and Fairooz Kabbinavar. “Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.” Oncology 69 Suppl 3 (2005): 17–24. https://doi.org/10.1159/000088480.
       Full Text  Link to Item
    • Sonpavde, Guru. “Bevacizumab in colorectal cancer.” N Engl J Med 351, no. 16 (October 14, 2004): 1690–91. https://doi.org/10.1056/NEJM200410143511622.
       Full Text  Link to Item
    • Blackwell, Kimberly, Herbert Hurwitz, Grazyna Liebérman, William Novotny, Stacey Snyder, Mark Dewhirst, and Charles Greenberg. “Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.” Cancer 101, no. 1 (July 1, 2004): 77–82. https://doi.org/10.1002/cncr.20336.
       Full Text  Link to Item
    • Hurwitz, Herbert, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, et al. “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.” N Engl J Med 350, no. 23 (June 3, 2004): 2335–42. https://doi.org/10.1056/NEJMoa032691.
       Full Text  Link to Item
    • Gerke, H., R. White, M. F. Byrne, H. Stiffier, R. M. Mitchell, H. I. Hurwitz, M. A. Morse, et al. “Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage.” Dig Liver Dis 36, no. 6 (June 2004): 412–18. https://doi.org/10.1016/s1590-8658(04)00096-9.
       Full Text  Link to Item
    • Collins, T. S., and H. I. Hurwitz. “The Damjanov/Meropol article reviewed.” Oncology 18, no. 4 (April 1, 2004): 488–93.
    • Rizvi, Naiyer A., Jeffrey S. Humphrey, Elizabeth A. Ness, Michael D. Johnson, Elora Gupta, Kathleen Williams, Diana J. Daly, et al. “A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.” Clin Cancer Res 10, no. 6 (March 15, 2004): 1963–70. https://doi.org/10.1158/1078-0432.ccr-1183-02.
       Full Text  Link to Item
    • Czito, Brian G., Timothy J. Hong, Darrel P. Cohen, Douglas S. Tyler, Catherine G. Lee, Mitchell S. Anscher, Kirk A. Ludwig, et al. “A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.” Int J Radiat Oncol Biol Phys 58, no. 3 (March 1, 2004): 779–85. https://doi.org/10.1016/S0360-3016(03)01567-0.
       Full Text  Link to Item
    • Hurwitz, H. I. “Introduction: Targeting angiogenesis in cancer therapy.” Oncologist 9, no. SUPPL. 1 (January 1, 2004): 1. https://doi.org/10.1634/theoncologist.9-suppl_1-1.
       Full Text
    • Hurwitz, H. “Integrating the anti-VEGF - A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.” Clinical Colorectal Cancer 4, no. SUPPL. 2 (January 1, 2004). https://doi.org/10.3816/CCC.2004.s.010.
       Full Text
    • Fernando, Nishan H., and Herbert I. Hurwitz. “Targeted therapy of colorectal cancer: clinical experience with bevacizumab.” Oncologist 9 Suppl 1 (2004): 11–18. https://doi.org/10.1634/theoncologist.9-suppl_1-11.
       Full Text  Link to Item
    • Micames, Carlos, Paul S. Jowell, Rebekah White, Erik Paulson, Rendon Nelson, Michael Morse, Herbert Hurwitz, Theodore Pappas, Douglas Tyler, and Kevin McGrath. “Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA.” Gastrointest Endosc 58, no. 5 (November 2003): 690–95. https://doi.org/10.1016/s0016-5107(03)02009-1.
       Full Text  Link to Item
    • Fernando, Nishan H., and Herbert I. Hurwitz. “Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.” Semin Oncol 30, no. 3 Suppl 6 (June 2003): 39–50. https://doi.org/10.1016/s0093-7754(03)00124-6.
       Full Text  Link to Item
    • Onaitis, Mark, Michael Morse, Herbert Hurwitz, Peggy Cotton, Douglas Tyler, Pierre Clavien, and Bryan Clary. “Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases.” Ann Surg 237, no. 6 (June 2003): 782–88. https://doi.org/10.1097/01.SLA.0000071561.76384.19.
       Full Text  Link to Item
    • Morse, Michael A., Smita K. Nair, Paul J. Mosca, Amy C. Hobeika, Timothy M. Clay, Yuping Deng, David Boczkowski, et al. “Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.” Cancer Invest 21, no. 3 (June 2003): 341–49. https://doi.org/10.1081/cnv-120018224.
       Full Text  Link to Item
    • Keefe, Francis J., Isaac Lipkus, John C. Lefebvre, Herbert Hurwitz, Elizabeth Clipp, Jill Smith, and Laura Porter. “The social context of gastrointestinal cancer pain: a preliminary study examining the relation of patient pain catastrophizing to patient perceptions of social support and caregiver stress and negative responses.” Pain 103, no. 1–2 (May 2003): 151–56. https://doi.org/10.1016/s0304-3959(02)00447-5.
       Full Text  Link to Item
    • Lockhart, A Craig, Rod D. Braun, Daohai Yu, Joel R. Ross, Mark W. Dewhirst, Jeffrey S. Humphrey, Seth Thompson, et al. “Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.” Clin Cancer Res 9, no. 2 (February 2003): 586–93.
       Link to Item
    • Kabbinavar, Fairooz, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, and Emily Bergsland. “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.” J Clin Oncol 21, no. 1 (January 1, 2003): 60–65. https://doi.org/10.1200/JCO.2003.10.066.
       Full Text  Link to Item
    • Lockhart, A Craig, Rod D. Braun, Daohai Yu, Joel R. Ross, Mark W. Dewhirst, Bruce Klitzman, Fan Yuan, et al. “A clinical model of dermal wound angiogenesis.” Wound Repair Regen 11, no. 4 (2003): 306–13. https://doi.org/10.1046/j.1524-475x.2003.11411.x.
       Full Text  Link to Item
    • Martell, Robert E., Bercedis L. Peterson, Harvey Jay Cohen, William P. Petros, Kanti R. Rai, Vicki A. Morrison, Laurence Elias, et al. “Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.” Cancer Chemother Pharmacol 50, no. 1 (July 2002): 37–45. https://doi.org/10.1007/s00280-002-0443-5.
       Full Text  Link to Item
    • Rizzieri, David A., Adam J. Bass, Gary L. Rosner, Jon P. Gockerman, Carlos M. DeCastro, William P. Petros, David J. Adams, et al. “Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.” J Clin Oncol 20, no. 3 (February 1, 2002): 674–79. https://doi.org/10.1200/JCO.2002.20.3.674.
       Full Text  Link to Item
    • Hurwitz, H. I., and P. J. Casey. “Prenylation of CaaX-type proteins: Basic principles through clinical applications.” Current Topics in Membranes 52 (January 1, 2002): 531–50. https://doi.org/10.1016/s1063-5823(02)52021-4.
       Full Text
    • Morse, Michael A., Smita K. Nair, David Boczkowski, Douglas Tyler, Herbert I. Hurwitz, Alan Proia, Timothy M. Clay, Jeffrey Schlom, Eli Gilboa, and H Kim Lyerly. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.” Int J Gastrointest Cancer 32, no. 1 (2002): 1–6. https://doi.org/10.1385/IJGC:32:1:1.
       Full Text  Link to Item
    • Onaitis, M. W., R. B. Noone, R. Fields, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, et al. “Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.” Ann Surg Oncol 8, no. 10 (December 2001): 801–6. https://doi.org/10.1007/s10434-001-0801-2.
       Full Text  Link to Item
    • White, R. R., H. I. Hurwitz, M. A. Morse, C. Lee, M. S. Anscher, E. K. Paulson, M. R. Gottfried, et al. “Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.” Ann Surg Oncol 8, no. 10 (December 2001): 758–65. https://doi.org/10.1007/s10434-001-0758-1.
       Full Text  Link to Item
    • Onaitis, M. W., R. B. Noone, M. Hartwig, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, et al. “Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.” Ann Surg 233, no. 6 (June 2001): 778–85. https://doi.org/10.1097/00000658-200106000-00007.
       Full Text  Link to Item
    • White, R. R., E. K. Paulson, K. S. Freed, M. T. Keogan, H. I. Hurwitz, C. Lee, M. A. Morse, et al. “Staging of pancreatic cancer before and after neoadjuvant chemoradiation.” J Gastrointest Surg 5, no. 6 (2001): 626–33. https://doi.org/10.1016/s1091-255x(01)80105-0.
       Full Text  Link to Item
    • Chakravarthy, A., R. A. Abrams, C. J. Yeo, L. T. Korman, R. C. Donehower, R. H. Hruban, M. L. Zahurek, et al. “Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.” Int J Radiat Oncol Biol Phys 48, no. 4 (November 1, 2000): 1089–96. https://doi.org/10.1016/s0360-3016(00)00755-0.
       Full Text  Link to Item
    • Ochoa, L., H. I. Hurwitz, G. Wilding, D. Cohen, J. P. Thomas, G. Schwartz, P. Monroe, et al. “Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.” Ann Oncol 11, no. 10 (October 2000): 1313–22. https://doi.org/10.1023/a:1008379802642.
       Full Text  Link to Item
    • Anscher, M. S., C. Lee, H. Hurwitz, D. Tyler, L. R. Prosnitz, P. Jowell, G. Rosner, T. Samulski, and M. W. Dewhirst. “A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer.” Int J Radiat Oncol Biol Phys 47, no. 3 (June 1, 2000): 719–24. https://doi.org/10.1016/s0360-3016(00)00473-9.
       Full Text  Link to Item
    • White, R., C. Lee, M. Anscher, M. Gottfried, R. Wolff, M. Keogan, T. Pappas, H. Hurwitz, and D. Tyler. “Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.” Ann Surg Oncol 6, no. 1 (1999): 38–45. https://doi.org/10.1007/s10434-999-0038-z.
       Full Text  Link to Item
    • Abrams, R. A., R. M. Cardinale, C. Enger, T. L. Haulk, H. Hurwitz, F. Osterman, and J. V. Sitzmann. “Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients.” Int J Radiat Oncol Biol Phys 39, no. 5 (December 1, 1997): 1077–85. https://doi.org/10.1016/s0360-3016(97)00389-1.
       Full Text  Link to Item
    • Jaffee, E. M., A. Lazenby, J. Meurer, F. Marshall, K. M. Hauda, C. Counts, H. Hurwitz, J. W. Simons, H. I. Levitsky, and D. M. Pardoll. “Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.” J Immunother Emphasis Tumor Immunol 18, no. 1 (July 1995): 1–9. https://doi.org/10.1097/00002371-199507000-00001.
       Full Text  Link to Item
    • Hurwitz, H. I., and W. P. McGuire. “Primary chemotherapy in epithelial ovarian cancer.” Obstet Gynecol Clin North Am 21, no. 1 (March 1994): 141–54.
       Link to Item
    • Ellman, M. H., H. Hurwitz, C. Thomas, and M. Kozloff. “Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.” J Rheumatol 18, no. 11 (November 1991): 1741–43.
       Link to Item

  • Conference Papers

    • Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.
       Full Text  Link to Item
    • Innocenti, F., C. Jiang, A. B. Sibley, S. Denning, A. S. Etheridge, D. Watson, D. Niedzwiecki, et al. “A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients.” In Ann Oncol, 29 Suppl 8:viii661–62, 2018. https://doi.org/10.1093/annonc/mdy303.038.
       Full Text  Link to Item
    • Berlin, Jordan, Ramesh K. Ramanathan, John H. Strickler, Deepa S. Subramaniam, John Marshall, Yoon-Koo Kang, Robert Hetman, et al. “A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.” In Br J Cancer, 118:938–46, 2018. https://doi.org/10.1038/s41416-018-0003-3.
       Full Text  Link to Item
    • Hainsworth, John D., Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard Burris, et al. “Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.” In J Clin Oncol, 36:536–42, 2018. https://doi.org/10.1200/JCO.2017.75.3780.
       Full Text  Link to Item
    • Hurwitz, H. I. “Highlights in metastatic colorectal cancer from the American Society of Clinical Oncology Annual Meeting, June 3-7, 2011, Chicago, Illinois.” In Clinical Advances in Hematology &Amp; Oncology : H&Amp;O, 9:1–24, 2011.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.